After Takeda's Phase 3 Topline Study Results For Soticlestat, Ovid Says It Will Prioritize And Pursue Its Programs With Financial Discipline And Expects Its Cash Runway To Last Into The First Half Of 2026
After Takeda's Phase 3 Topline Study Results For Soticlestat, Ovid Says It Will Prioritize And Pursue Its Programs With Financial Discipline And Expects Its Cash Runway To Last Into The First Half Of 2026
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.